We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » J&J Alleges Amgen’s Proposed Biosimilar Infringes on Stelara Patents
J&J Alleges Amgen’s Proposed Biosimilar Infringes on Stelara Patents
Johnson & Johnson (J&J) has sued Amgen for allegedly violating its patent protections for blockbuster Stelara (ustekinumab) — a biologic FDA-approved for treating ulcerative colitis, psoriatic arthritis, plaque psoriasis and Crohn’s disease, among other indications.